Related Experiment Videos
[Anticoagulation and antiaggregation in cardiac patients]
1Herzzentrum Bern, Bern. meyer@herzzentrum-bern.ch
Insights
Aspirin and clopidogrel are effective in preventing cardiovascular events, but increase bleeding risk. Guidelines now cover managing atrial fibrillation and anticoagulation in heart valve patients.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Aspirin is beneficial for primary prevention of coronary events at high risk.
- Aspirin and clopidogrel reduce cardiovascular events in coronary disease patients.
- Combining aspirin with clopidogrel offers additional event reduction but increases bleeding risk.
Purpose of the Study:
- To review current recommendations for preventing thromboembolic events and bleeding complications.
- To outline recommended antithrombotic therapy intensity.
- To summarize key guidelines for managing atrial fibrillation patients.
Main Methods:
- Review of recent studies on myocardial infarction treatments.
- Analysis of risks associated with therapeutic anticoagulation.
- Synthesis of guidelines for valvular heart disease and prosthetic valve management.
Main Results:
- Aspirin is safe and effective for primary prevention with an annual coronary event risk of 1.5% or higher.
- Combined aspirin and clopidogrel reduce cardiovascular events but increase bleeding risk.
- Coumadin-based therapies show comparable effectiveness to aspirin alone in myocardial infarction patients.
Conclusions:
- Antithrombotic therapy requires careful balancing of efficacy and bleeding risk.
- Specific guidelines are crucial for managing patients with atrial fibrillation and valvular heart disease.
- Optimized antithrombotic strategies are essential for preventing thromboembolic and bleeding complications.
Abstract:
Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1.5%. Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary disease. Clopidogrel in addition to aspirin further reduces cardiovascular events, but is associated with and increased bleeding risk. Recent studies in patients with myocardial infarction suggest that treatment with either coumadin or with coumadin and aspirin are both at least as effective than treatment with aspirin alone. Thromboembolism and bleeding during therapeutic anticoagulation are the major chronic risks for patients with native valvular heart disease and mechanical prosthetic valves. The recommendations for the prevention of thromboembolic events and bleeding complications are discussed and recommended intensity of antithrombotic therapy are outlined. Key points of the guidelines for managing patients with atrial fibrillation are summarised.